GOFYXII
LIVE

Serial Number

97772656

Owner

CSL BEHRING GMBH

Attorney

Scott D. Woldow

Filing Date

Jan 30, 2023

Add to watchlist:

No watchlists yet
View on USPTO

GOFYXII Trademark

Serial Number: 97772656 • Registration: 7202080

GOFYXII is a trademark filed by CSL BEHRING GMBH on January 30, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CSL BEHRING GMBH (101 trademarks)

EMIL-VON-BEHRING STRASSE 76
MARBURG (LAHN) , DE

Entity Type: 16

Trademark Details

Filing Date

January 30, 2023

Registration Date

October 24, 2023

Published for Opposition

August 8, 2023

Goods & Services

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 24, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 24, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 8, 2023 NPUB
PUBLISHED FOR OPPOSITION
Aug 8, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 19, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 30, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 30, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 30, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 26, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 23, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 23, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 23, 2023 CNRT
ASSIGNED TO EXAMINER
May 16, 2023 DOCK
PETITION TO DIRECTOR - MAKE SPECIAL - GRANTED
May 15, 2023 PMSG
ASSIGNED TO PETITION STAFF
May 15, 2023 APET
TEAS PETITION TO DIRECTOR-MAKE SPECIAL-RECEIVED
May 8, 2023 TPMS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 16, 2023 NWOS
NEW APPLICATION ENTERED
Feb 2, 2023 NWAP